Roche sets sights on Novartis, Biogen as SMA trial hits target
(Reuters Health)

Roche`s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.